Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Macquarie Upgrade Halts The Group Selling Spree Of Groupon Inc (GRPN)’s Shares

Page 1 of 2

Shares of Chicago-based Groupon Inc (NASDAQ:GRPN) are up by more than 4.95% after an upgrade from Macquarie to ‘Outperform’ from an earlier ‘Neutral’ rating. The price target however was lowered to $7.00 from $7.75, though that still provides an upside of more than 36% from the current trading price of shares. The rationale behind this development was that shares were being oversold and have already fallen to the tune of 29% after the $3.29 billion provider of online discounts delivered its first quarter financial results. Groupon Inc (NASDAQ:GRPN)’s stock is still trading nearly 40% below its 52-week high and has lost about 38% of its value so far this year. This is much worse than the 3.16% average gains that the internet content & information industry has posted during the same time period.


Professional money managers probably realized the oversold nature of the stock, and hence the company saw a rise in interest from hedge funds during the first quarter, at least in terms of overall number of investors. Among the funds that we track, a total of 35 had invested about $419.70 million in Groupon Inc (NASDAQ:GRPN), as compared to 30 firms with $530.09 million at the end of the previous quarter. As you can see, the total value of their holdings did decline by over 20% during the quarter, though the shares fell by over 15% in value, so despite more investors, they collectively owned less shares.

An everyday investor does not have the time or the required skill-set to carry out an in-depth analysis of equities and identify companies with the best future prospects like a fund with the knowledge and resources of Visium can. However, it is also not a good idea to pay the egregiously high fees that investment firms charge for their stock picking expertise. Thus a retail investor is better off to monkey the most popular stock picks among hedge funds by him or herself. But not just any picks mind you. Our research has shown that a portfolio based on hedge funds’ top stock picks (which are invariably comprised entirely of large-cap companies) falls considerably short of a portfolio based on their best small-cap stock picks. The most popular large-cap stocks among hedge funds underperformed the market by an average of seven basis points per month in our back tests whereas the 15 most popular small-cap stock picks among hedge funds outperformed the market by nearly a percentage point per month over the same period between 1999 and 2012. Since officially launching our small-cap strategy in August 2012 it has performed just as predicted, beating the market by over 80 percentage points and returning over 135%, while hedge funds themselves have collectively underperformed the market (read the details here).

Another useful indicator of a company’s future prospects is insider trading. However, it must be noted that insider purchases are a much stronger indicator than insider selling, which can occur owing to a large set of reasons. Although no insider purchases have been detected in Groupon Inc (NASDAQ:GRPN) this year, prominent insider selling transactions include that by Director Bradley Keywell, who has disposed of 3.5 million shares so far this year, and by CEO Eric Lefkofsky, who liquidated some 2.27 million shares during the same period.

Let’s look next at the smart money activity in Groupon’s shares.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!